共 6 条
[1]
[2]
Determination of tegafur; 5-fluorouracil; gimeracil and oxonic acid in human plasma using liquid chromatography–tandem mass spectrometry[J] Ke Liu;Dafang Zhong;Huiyu Zou;Xiaoyan Chen Journal of Pharmaceutical and Biomedical Analysis 2010,
[3]
Pharmacokinetics of S-1 in patients with peritoneal dissemination ofgastric cancer[J] Takashi Oshima;Roppei Yamada;Shinsuke Hatori;Chikara Kunisaki;Toshio Imada Oncology Reports 2006,
[4]
Phase I study of S-1 and biweekly docetaxel combination chemotherapyfor advanced and recurrent gastric cancer[J] Ikuo Takahashi;Yasunori Emi;Yoshihiro Kakeji;Eriko Tokunaga;Shin Ushiro;Eiji Oki;Masayuki Watanabe;Hideo Baba;Yoshihiko Maehara Oncology Reports 2006,
[5]
Comparison of the Pharmacokinetics of S-1; an Oral Anticancer Agent; in Western and Japanese Patients[J] Emmanuelle Comets;Kazumasa Ikeda;Paulo Hoff;Pierre Fumoleau;Jantien Wanders;Yusuke Tanigawara Journal of Pharmacokinetics and Pharmacodynamics 2003,
[6]
Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2;4-dihydroxypyridine (CDHP) in human tumour cells[J] T Takechi;A Fujioka;E Matsushima;M Fukushima European Journal of Cancer 2002,

